Form 4: Capricor Therapeutics CFO Sells Shares Under 10b5-1 Plan

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, has sold 25,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Anthony Bergmann, Chief Financial Officer of Capricor Therapeutics, Inc., reported a transaction on May 1, 2026.
• He acquired 25,000 shares of common stock at a price of $3.18 per share.
• Subsequently, he disposed of 25,000 shares of common stock at a weighted average price of $31.70, with individual sales ranging from $30.89 to $33.19.
• These sales were executed under a Rule 10b5-1 trading plan established in December 2025.
• Following these transactions, Bergmann beneficially owns 8,223 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale by a key executive, despite the use of a 10b5-1 plan. While the plan itself is a positive governance practice, the sheer volume of shares sold could be perceived as a bearish signal by some investors.

Positives

• The sale was conducted under a pre-established 10b5-1 plan, indicating adherence to a structured trading strategy designed to avoid insider trading concerns.
• The acquisition of shares at a lower price ($3.18) before the sale at a significantly higher price ($31.70 weighted average) suggests a profitable execution of the plan.

Negatives

• A significant number of shares (25,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale represents a substantial portion of the shares acquired under the plan.

Risks

• The sale of shares by a high-ranking executive could be interpreted as a lack of confidence in the company's immediate future prospects, potentially impacting investor sentiment.
• The weighted average sale price of $31.70 is significantly higher than the acquisition price of $3.18, indicating a substantial profit for the executive, which might raise questions about the timing of the sale relative to potential future price movements.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.89 to $33.19, inclusive.
• Shares vested 1/48th on the first day of each month commencing February 1, 2022.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors. The use of a 10b5-1 plan is a standard practice to facilitate planned stock sales while adhering to insider trading regulations. The significant difference between the acquisition and sale price for Mr. Bergmann's shares is noteworthy, though the specific context of Capricor Therapeutics' stock performance and the rationale behind the 10b5-1 plan's parameters would require further investigation.

Corporate Governance

Stakeholder Impact

• Shareholders: May perceive the sale by a key executive as a negative signal, potentially impacting short-term stock performance, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees: May be influenced by executive trading activity, though the primary impact is on investor sentiment.
• Management: The transaction reflects a planned liquidity event for the CFO, executed within regulatory guidelines.

Next Steps

• Monitor future Form 4 filings for any additional transactions by Mr. Bergmann or other insiders.
• Analyze Capricor Therapeutics' upcoming financial reports and press releases for strategic updates that might influence stock price.

Key Dates

Recommendation

The filing reports a routine insider sale under a 10b5-1 plan. While the sale of a significant number of shares by the CFO could be a short-term negative catalyst, the use of a pre-arranged plan suggests it's not necessarily a reflection of negative non-public information. A 'hold' recommendation is appropriate pending further company-specific news or financial performance indicators.

Keywords

Form 4, SEC Filing, Insider Trading, 10b5-1 Plan, Stock Sale, Capricor Therapeutics, CAPR, Anthony Bergmann, Beneficial Ownership, Common Stock, Executive Compensation